trial
as of 2026-07-01Varenicline for Cognitive Deficits and Cigarette Smoking in Schizophrenia - Efficacy and Predictors
NCTId NCT00802919
at a glance
Phase 4 · Completed
Enrollment 93 (actual)
Sponsored by Nathan Kline Institute for Psychiatric Research
Primary completion 2013-12
Synthesized from structured facts only — each point cited above.
Design & status
Phase
Phase 4
Status
Completed
Enrollment
93 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Double
Start
2008-09
Primary completion
2013-12
Eligibility
ALL · 18 Years · 65 Years
Interventions & indications
Sponsors
Nathan Kline Institute for Psychiatric ResearchLead Sponsor
Investigators
1
Robert C. Smith, MD, PhDPrincipal Investigator
Sites
4 total
New York, United StatesOrangeburg, United StatesBeijing, ChinaTel Litwinsky, Israel
Facts & assertions
4 sourced
Enrollment
93
Phase
PHASE4
Primary Completion Date
2013-12
Status
COMPLETED
relationships
The graph out of here
drug
drug
lead_sponsor
indication
investigator
person